Eli Lilly and Company (LLY)
| Market Cap | 1.02T +42.2% |
| Revenue (ttm) | 72.25B +47.4% |
| Net Income | 25.28B +127.6% |
| EPS | 28.15 +129.1% |
| Shares Out | 891.74M |
| PE Ratio | 40.81 |
| Forward PE | 32.16 |
| Dividend | $6.92 (0.60%) |
| Ex-Dividend Date | Aug 14, 2026 |
| Volume | 2,884,614 |
| Open | 1,148.51 |
| Previous Close | 1,154.97 |
| Day's Range | 1,119.00 - 1,150.63 |
| 52-Week Range | 623.78 - 1,249.45 |
| Beta | 0.51 |
| Analysts | Buy |
| Price Target | 1,276.96 (+11.15%) |
| Earnings Date | Aug 5, 2026 |
About LLY
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi... [Read more]
Financial Performance
In 2025, Eli Lilly's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.
Financial StatementsAnalyst Summary
According to 28 analysts, the average rating for LLY stock is "Buy." The 12-month stock price target is $1,276.96, which is an increase of 11.15% from the latest price.
News
Eli Lilly says FDA grants Breakthrough Therapy designation to olomorasib
Eli Lilly (LLY) and Company announced that the U.S. FDA has granted Breakthrough Therapy designation to olomorasib as a monotherapy for the treatment of adult patients with advanced pancreatic cancer…
Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer
INDIANAPOLIS, Aug. 3, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olomorasib...
Obesity battle heats up again as Novo claws way back into race with Lilly
Novo Nordisk investors have found little cause for optimism during a bruising two-year period of profit warnings, leadership upheaval and a sliding share price as rival Eli Lilly streaked ahead. Now ...
Jobs Report, Palantir, AMD, SpaceX, Eli Lilly, and More to Watch This Week
In another heavy earnings week, we'll also see reports from McDonald's, Disney, Uber, Devon Energy, and more.
Novo Nordisk Wipes Out $30 Billion In Market Value After Failed Heart Drug Trial
$30.7 billion. That's how much was cut from Novo Nordisk's market capitalization as of Friday's share price, lowering from $229.2 billion to $198.5 billion, marking a nearly 69% decline since hitting ...
Eli Lilly (LLY) Is Investing Another $750 Million in Its U.S. Manufacturing Capacity
The company is spending a total of $55 billion on U.S. manufacturing.
Lilly, Resilience to invest $750 million in US drug manufacturing expansion
Drugmaker Eli Lilly and privately held contract manufacturer Resilience will invest $750 million to expand pharmaceutical manufacturing capacity in the U.S. and strengthen the domestic medicine supp...
These 2 stocks are worth watching amidst ongoing stock market rotation
The benchmark S&P 500 index has spent the summer coiled in a tight range just below its “short-term moving averages,” currently down over 3% from its June high. Beneath this surface-level stillness, a...
Goldman Sachs Forecasts Weak Obesity Pill Sales from Eli Lilly (LLY)
The pharma giant’s weight-loss pill was approved on April 1 of this year.
Novo Nordisk Pursues Injunction to Block Eli Lilly’s (LLY) Advertisements
The two companies dominate the market for obesity medications.
As Lilly and Novo Clash in Court, Wall Street Is Eyeing This Bigger Prize
The legal battle between Novo Nordisk and Eli Lilly is escalating, but analysts are more focused on developments in the lab.
Novo Nordisk Seeks Injunction Against Eli Lilly in Dispute Over Weight-Loss Ads
Friday's preliminary injunction request escalates legal proceedings initiated earlier this week.
Novo Nordisk seeks preliminary injunction against Lilly weight-loss ads
Novo Nordisk said on Friday it is seeking a preliminary U.S. court injunction to immediately block obesity and diabetes drug advertisements by Eli Lilly , in a further escalation of the rivalry bet...
Lilly's Next-Generation Obesity Shot Clears Another Hurdle
Eli Lilly & Co.'s next-generation weight-loss shot retatrutide didn't increase overall heart risk in a new study, helping dispel concerns over its potential. The company plans to file for US Food and ...
Eli Lilly (LLY) Targets 2027 for Approval of Its Next-Generation Obesity Drug
The new medication helps people who also have diabetes and cardiovascular disease.
Eli Lilly Will File For Retatrutide Approval—As Study Shows Average Weight Loss Of 56 Pounds
Analysts have suggested retatrutide could become a blockbuster weight loss drug if approved. In January, TD Cowen analysts estimated retatrutide could generate $3.8 billion in sales in 2030, while Glo...
Eli Lilly notes retatrutide met primary endpoint in TRIUMPH-2, TRIUMPH-3 trials
Eli Lilly (LLY) announced topline results from TRIUMPH-2 and TRIUMPH-3, two Phase 3 trials evaluating retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor a...
Eli Lilly Preparing Retatrutide Applications After Positive Weight-Loss Data
Eli Lilly is preparing application materials for its next-generation weight-loss drug, retatrutide, following data from two Phase 3 trials showing the treatment delivered substantial results.
Lilly announces more next-gen obesity drug data, plans Q1 2027 FDA application
Eli Lilly on Thursday said two more Phase 3 trials of its experimental obesity drug retatrutide showed positive results and it plans to submit an application to the U.S. Food and Drug Administration ...
Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials
Eli Lilly said it will file for approval of its next-generation obesity drug, retatrutide, in the first quarter of 2027, as it succeeds in two more late-stage trials. The drug delivered significant w...
Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
In TRIUMPH-2, adults with obesity or overweight and type 2 diabetes, a population with increased difficulties losing weight, lost up to an average of 49.6 lbs (20.8%) at 80 weeks In TRIUMPH-3, adults ...
Weight loss drugs linked to increase risk of hair loss
Weight loss drugs such as Mounjaro, Ozempic and Wegovy are linked to an increased risk of hair loss, according to researchers.
Hair loss with GLP-1 drugs is rare, but real, studies find
The risk of hair loss in patients taking GLP-1 drugs for obesity or diabetes, while low, is higher than with other diabetes drugs, new studies suggest.
Lilly confirms date and conference call for second-quarter 2026 financial results announcement
INDIANAPOLIS, July 22, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2026 financial results on August 5, 2026. Lilly will also conduct a conference call that ...
Many US patients opt for obesity drug injections, defying some expectations
Many patients have opted for injectable forms of the wildly popular GLP-1 obesity medications through a pilot program of the U.S. government's Medicare health insurance program for Americans aged 65 ...